Egypt's Drug Authority reassures public on strategic reserves

The Egyptian Drug Authority EDA has confirmed the stability of the domestic pharmaceutical market, attributing it to precise monitoring and proactive measures against global supply chain shifts. Ali El-Ghamrawy, Chairman of the EDA, stated that the state supports local medicine availability and aims to boost exports. Yassin Ragai, Assistant Chairman of the EDA, noted that strategic stocks for essential medicines and biological preparations, including treatments for blood pressure, diabetes, heart diseases, oncology, and complex biologicals, cover up to six months for most products. Approximately 55 percent of raw materials for the current year have been imported, and local stocks meet most consumer needs. Ragai also highlighted that 80 percent of active ingredients have over three months' stock for production, and local manufacturing of necessary medicines has reached 91 percent, reducing import reliance. The EDA monitors pharmaceutical shipments daily to ensure continuous supply chains and raw material availability. Pharmaceutical exports grew to $1.3 billion in 2025, reaching 147 countries, a growth rate exceeding 20 percent.